Abstract: An electric current measurement method is provided with: a first controlling process of sweeping a sensing current in a negative magnetization direction in a condition that a core is saturated magnetically in a positive magnetization direction; a second controlling process of sweeping the sensing current in the positive magnetization direction in a condition that the core is saturated magnetically in the negative magnetization direction; a first specifying process of specifying a value of the sensing current if the core is demagnetized in the first controlling process; a second specifying process of specifying a value of the sensing current if the core is demagnetized in the second controlling process; and a calculating process of calculating a value of a target electric current on the basis of the specified current values, the first and second controlling processes being performed repeatedly.

Abstract: An electric current measurement method is provided with: a first controlling process of sweeping a sensing current in a negative magnetization direction in a condition that a core is saturated magnetically in a positive magnetization direction; a second controlling process of sweeping the sensing current in the positive magnetization direction in a condition that the core is saturated magnetically in the negative magnetization direction; a first specifying process of specifying a value of the sensing current if the core is demagnetized in the first controlling process; a second specifying process of specifying a value of the sensing current if the core is demagnetized in the second controlling process; and a calculating process of calculating a value of a target electric current on the basis of the specified current values, the first and second controlling processes being performed repeatedly.

Abstract: Fusion protein including a fusion part and a protein of interest, the combination of the two proteins leading to the fusion protein being secreted into a supernatant of a bacterial host with the protein of interest being present in its correct three-dimensional structure. Nucleic acid including a sequence coding for a fusion protein, the sequence including: —F—Asm—Rn—Y—, where F is a nucleic acid sequence coding for an amino acid sequence which allows secretion of a protein encoded by Y into a fermentation medium, As is a chemical bond or a nucleic acid sequence comprising a codon, m is an integer from 0–10, R is a chemical bond or an arginine codon, n is 0 or 1, and Y is a nucleic acid sequence coding for a protein of interest. Processes therefor.

Abstract: Three phase input voltage systems and three phase output voltage systems connected between a first rail and a second rail. Each of the three phase input voltage system includes an interruptible power transistor. Two series connected reverse diodes are connected in parallel with the interruptible power transistor. The phase input voltage system is connected with a node of the series connected reverse diodes.

Abstract: The invention relates to insulin analogs exhibiting enhanced zinc binding capacity and to stable zinc complexes thereof having a retarded activity in comparison with human insulin. The invention further relates to a method for the production of said insulin analogs and to their use, particularly in pharmaceutical preparations for therapy of type I and type II diabetes mellitus.

Abstract: The invention relates to a precursor of human insulin or of an insulin analog of the formula I: Fus-B(1-30)-RDVP-Yn-A(1-21)  (I); wherein Fus is an optionally present fusion portion; B(1-30) is a B chain of human insulin, Y is an amino acid chain which terminates with a basic amino acid at the C terminus; n is from 2 to 50 and indicates the length of the amino acid chain Y; and A(1-21) is an A chain of human insulin, and the A chain and/or the B chain can be modified by amino acid substitution, deletions and/or additions. The present invention also provides DNA coding for the above precursors, preparation and use of the instant precursors and DNA, and a process for preparing human insulin or an insulin analog.

Abstract: Fusion protein including a fusion part and a protein of interest, the combination of the two proteins leading to the fusion protein being secreted into a supernatant of a bacterial host with the protein of interest being present in its correct three-dimensional structure. Nucleic acid including a sequence coding for a fusion protein, the sequence including: —F—Asm—Rn—Y—, where F is a nucleic acid sequence coding for an amino acid sequence which allows secretion of a protein encoded by Y into a fermentation medium, As is a chemical bond or a nucleic acid sequence comprising a codon, m is an integer from 0-10, R is a chemical bond or an arginine codon, n is 0 or 1, and Y is a nucleic acid sequence coding for a protein of interest. Processes therefor.

Abstract: Includes three phase input voltage systems and three phase output voltage systems connected between a first rail and a second rail. Each of the phase input voltage system includes an interruptible power transistor. Two series connected reverse diodes are connected in parallel with the interruptible power transistor. The phase input voltage system is connected with a node of the series connected reverse diodes.

Abstract: The invention relates to pharmaceutical agents containing leptin antagonists for treating Type II diabetes. One leptin antagonist is based on a murine leptin fragment and comprises amino acids 116 to 167 or 116 to 166. Methods of treating Type II diabetes are also disclosed.

Abstract: The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent.

Abstract: Insulin derivatives with increased zinc binding where Z is a histidine residue or a peptide having 2 to 35 genetically encodable amino acid residues, having 1 to 5 histidine residues, are suitable for the production of pharmaceutical preparations for the treatment of diabetes. Insulins of the formula I form complexes with zinc++, comprising an insulin hexamer and approximately 5 to 9 mol of zinc++ per hexamer.